August 30, 2015
Recommended Topic Related To:

Oncaspar

"The U.S. Food and Drug Administration today approved Farydak (panobinostat) for the treatment of patients with multiple myeloma.

Multiple myeloma is a form of blood cancer that arises from plasma cells, a type of white blood cell, found in "...

Oncaspar




Overdosage
Contraindications

OVERDOSE

Three patients received 10,000 International Units/m² of Oncaspar® as an intravenous infusion. One patient experienced a slight increase in liver enzymes. A second patient developed a rash 10 minutes after the start of the infusion, which was controlled with the administration of an antihistamine and by slowing down the infusion rate. A third patient did not experience any adverse reactions.

CONTRAINDICATIONS

  • History of serious allergic reactions to Oncaspar® .
  • History of serious thrombosis with prior L-asparaginase therapy.
  • History of pancreatitis with prior L-asparaginase therapy.
  • History of serious hemorrhagic events with prior L-asparaginase therapy.

Last reviewed on RxList: 5/2/2014
This monograph has been modified to include the generic and brand name in many instances.

Overdosage
Contraindications

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.